Curevac receives u.s. fda ind clearance to initiate phase 1 clinical trial for novel mrna-based precision immunotherapy in squamous non-small cell lung cancer

Significant regulatory milestone: u.s. fda cleared ind application for cvhnlc, curevac's investigational therapy targeting squamous non-small cell lung cancer proprietary epitopes: cvhnlc encodes novel tumor epitopes identified through proprietary whole genome-based discovery platform enhanced combination therapy: cvhnlc to be tested in combination with pembrolizumab, aiming to amplify targeted anti-tumor immune responses clinical progress: patient treatment anticipated to start in the second half of 2025 pipeline advancement: ind clearance highlights curevac's continued oncology pipeline growth, with more candidates planned to enter the clinic in 2026 tÜbingen, germany and boston, ma / access newswire / april 7, 2025 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the u.s. food and drug administration (fda) has cleared its investigational new drug (ind) application for a phase 1 clinical study of cvhnlc in patients with squamous non-small cell lung cancer (sqnsclc).
CVAC Ratings Summary
CVAC Quant Ranking